Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. [electronic resource]
Producer: 20070501Description: 899-906 p. digitalISSN:- 0008-543X
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Azacitidine -- administration & dosage
- Benzamides
- Blast Crisis -- drug therapy
- DNA Methylation
- Decitabine
- Female
- Genes, abl
- Humans
- Imatinib Mesylate
- Male
- Middle Aged
- Piperazines -- administration & dosage
- Polymerase Chain Reaction
- Pyrimidines -- administration & dosage
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.